Literature DB >> 2845994

Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta. Separation and inhibition by selective reference phosphodiesterase inhibitors.

A F Prigent1, S Fougier, G Nemoz, G Anker, H Pacheco, C Lugnier, A Lebec, J C Stoclet.   

Abstract

The resolution as well as the biochemical properties of the multiple molecular forms of cyclic nucleotide phosphodiesterase, in a given tissue, may be strongly dependent upon experimental conditions of preparation (extraction of crude enzyme from tissues and fractionation procedures). In the present study, we compare the different molecular forms of cardiac (rat heart ventricle) and vascular (bovine aorta) phosphodiesterase isolated from crude extracts prepared either in sucrose medium or in hypotonic medium (in the presence of protease inhibitors and ion chelators) using two different fractionation procedures: isoelectric focusing on flat gel bed and DEAE-Trisacryl anion exchange chromatography. Both the calmodulin-dependent and the cAMP-specific forms exhibited close IEF and chromatographic patterns and showed similar sensitivities towards reference inhibitors regardless of the tissue of origin. In marked contrast, the cGMP-specific isoform notably differed from one to another tissue with respect to its biochemical properties (only the cardiac tissue being capable of stimulation by cGMP) and sensitivities to xenobiotics. Thus the possibility exists that pharmacological agents may modulate phosphodiesterase activity differently in cardiac and vascular target tissues.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845994     DOI: 10.1016/0006-2952(88)90400-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Species differences in localization of cardiac cAMP-phosphodiesterase activity: a cytochemical study.

Authors:  L Okruhlicová; N Tribulová; J Styk; A Eckly; C Lugnier; J Slezk
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices.

Authors:  R A Challiss; C D Nicholson
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

3.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

4.  Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes.

Authors:  Mark T Ziolo; Susanne J Lewandowski; Jacquelyn M Smith; Fred D Romano; Gordon M Wahler
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 5.  Purine metabolism in the heart. Strategies for protection against myocardial ischaemia.

Authors:  K Ver Donck
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.

Authors:  E J Kelso; B J McDermott; B Silke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.

Authors:  G Dent; M A Giembycz; K F Rabe; P J Barnes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

8.  Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2016-01-07       Impact factor: 5.000

9.  Cytochemical distribution of cyclic AMP-dependent 3',5'-nucleotide phosphodiesterase in the rat myocardium.

Authors:  L Okruhlicová; N Tribulová; A Eckly; C Lugnier; J Slezák
Journal:  Histochem J       Date:  1996-03

Review 10.  Cyclic GMP and PKG Signaling in Heart Failure.

Authors:  Genri Numata; Eiki Takimoto
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.